Capricor Therapeutics Inc
NASDAQ:CAPR
Capricor Therapeutics Inc
Intangible Assets
Capricor Therapeutics Inc
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Capricor Therapeutics Inc
NASDAQ:CAPR
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Intangible Assets
$52.6B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Intangible Assets
$17B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Intangible Assets
$22.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
6%
|
CAGR 10-Years
7%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Intangible Assets
$424.2m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Intangible Assets
$1.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Capricor Therapeutics Inc
Glance View
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. The company is headquartered in Beverly Hills, California and currently employs 48 full-time employees. The company went IPO on 2002-06-04. The firm consists of cell therapy program, including CAP-1002 for Duchenne Muscular Dystrophy program and CAP-1002 with CAP-1002 for coronavirus (COVID-19). The Company’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is in clinical development for treating Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also developing its exosome technology therapeutic platform. The firm is focused on developing exosomes capable of delivering nucleic acids, including messenger RNA (mRNA) as well as proteins, to treat or prevent a range of diseases. CAP-1002 cell therapy programs initiated Pivotal Phase III, HOPE-3.
